Navigation Links
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
Date:5/16/2008

TYKERB.

TYKERB has been associated with interstitial lung disease and pneumonitis. Discontinue TYKERB if patients experience severe pulmonary symptoms.

TYKERB prolongs the QT interval in some patients. Consider ECG and electrolyte monitoring.

Fetal harm can occur when administered to a pregnant woman. Women should be advised not to become pregnant when taking TYKERB.

The most common adverse events (>20 percent) during treatment with TYKERB plus capecitabine were diarrhea, vomiting, nausea, fatigue, palmar-plantar erythrodysethesia, and rash.

Please see full prescribing information.

Cautionary Statement Regarding Forward-Looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Notes to editors:

TYKERB(R) is a registered trademark of the GlaxoSmithKline group of companies in the United States.

TYVERB(R) is a registered trademark of the GlaxoSmithKline group of companies in Europe and is the proposed trade name in certain markets, pending regulatory approval. TYVERB is currently not licensed in Europe.

HERCEPTIN(R) is a registered trademark of Genentech, Inc.

For on-site contact at ASCO 30 May - 3 June 2008:

U.S media only: Sarah Alspach - +1 215 287 6354

Global media: Gregory Clarke - +1 317 694 3545

European media: Sonja Luz - +44 792 056 8625

Enquiries:

US Media enquiries: Mary Anne Rhyne +1 919 483 2839

UK Media enquiries: Philip Thomson +44 20
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
4. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
5. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
6. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...a/--ChindexInternational,Inc.,("Chindex")(Nasdaq: ...n,healthcareproductsandservicesinthePeople,sRepubl...he21stAnnualPiperJaffray,"Unplugged"HealthCareConf...eHotel. , Managementiscurrentlyscheduledtopre...e-on-onemeetingsthroughouttheday.Awebcast,ofthepre...
(Date:11/24/2009)...ll/--AnadysPharmaceuticals,Inc.(Nasdaq: ANDS )anno...frayHealthcareConferenceonTuesday,December1,2009at...tTheNewYorkPalaceHotel.SteveWorland,Ph.D.,Presiden...rviewofAnadysanditsclinicaldevelopmentprograms,ANA...simultaneouslywebcastandcanbeaccessedontheInvestor...
(Date:11/24/2009)...-ZargisMedicalCorp.,asubsidiaryofSpeedusCorp.(Nasd...(NYSE: SI ),todayannouncedthatitsZargisCardioscand...TheEarlyShow duringasegmentinwhichMarkJannot,theed...productsfromthepublication,s2009"BestofWhat,sNew"a...ionmorningnewstalkshowbroadcastbyCBSfromNewYorkCit...
Breaking Medicine Technology:Chindex International to Present at Piper Jaffray Health Care Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Cystic Fibrosis Treatment May Cause Hearing Loss 50673 1Cardinal Health Appoints Bruce Downey to Board of Directors 3B John McCoy Retires From Board After 22 Years 50670 1Cardinal Health Appoints Bruce Downey to Board of Directors 3B John McCoy Retires From Board After 22 Years 50670 2CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 1CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 2CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications 50667 3
...mmary: Proprietary DNA delivery technology enables...cells - reduces,atherosclerosis progression in mou...WIRE)--Mar 26, 2007 - Research conducted,at Clevel...lege of,Cardiology,s 58th Annual Scientific Sessio...ing the anti-inflammatory protein,interferon-beta ...
...ISIS 301012 coadministered with statins for only f...the levels achieved with,statins alone, with simil..., NEW ORLEANS and CARLSBAD, Calif., March 26, 2007...nc. announced new,results from its Phase 2 clinica... presented today at the of Cardiology,Annual Scien...
Other Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
(Date:11/25/2009)...rMadeinSupportofFeedingAmerica,sSNAPOutreachEffort...edingAmerica,thenation,slargesthunger-relieforgani...ofAmericaCharitableFoundationtosupportFeedingAmeri...lementalNutritionAssistanceProgram(SNAP),formerlyn...edingAmericafoodbanksimproveaccessandprovidepre-sc...
(Date:11/25/2009)... essential to normal human development - the Wnt/W... (EGFR) pathways - interact in ways that can promo... from The University of Texas M. D. Anderson Cance... Cell . , This newly characterized interaction i...ate with invasive cancer - activation of EGFR, ele...
(Date:11/25/2009)...n R. Kaplan, MD, FACP, a former Board Chair and on...ecame Los Angeles Biomedical Research Institute at...onored by the American College of Physicians for h...At its April 22, 2010 meeting in Toronto, the Amer... with the Ralph O. Claypoole Sr. Memorial Award fo...
(Date:11/25/2009)...at UT Southwestern Medical Center soon will begin ...ing in patients with upper spinal-cord injuries or...pendently. , UT Southwestern University Hospita... and one of 25 in the country currently equipped t...acing System. , The device is designed to give p...
(Date:11/25/2009)...ial function plays in insulin production , ...ondrial damage causes people with type 2 diabetes ...uld lead to new treatments, U.S. researchers say. ...vity. , The researchers found that when insulin...d to circulating insulin, it triggers a "molecular...
Breaking Medicine News(10 mins):Health News:Bank of America Charitable Foundation Presents $1 Million Contribution to Feeding America in an Effort to Help Connect Low-Income Americans With Federal Nutrition Programs 2Health News:Bank of America Charitable Foundation Presents $1 Million Contribution to Feeding America in an Effort to Help Connect Low-Income Americans With Federal Nutrition Programs 3Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 3Health News:1 of LA BioMed's founders to be honored 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2
...sue alive, benefits other organs, study finds , ...ared to CPR alone, adding extracorporeal life supp...diac arrest, says a study by researchers at the Na...point blood travels through the catheter via a pum...
...premier research company in San Jose, releases sev...report provides a comprehensive insight into the p...luencing the market, growth drivers, and major cha... San Jose, CA (PRWEB) July 9, 20...
...ation that would cut $268 million,from Medicare Ad... Seniors across Minnesota,are speaking out against...n,legislation being considered in the U.S. Senate....are private,fee-for-service plans can operate, adv...
...dical care for the uninsured, human,services, and ...y 9 Blue Cross and Blue Shield,of Illinois (BCBSI...organizations in Illinois. In line with its missio... mostly on,community-based organizations that prov...
...experts at the University of Alabama at Birmingham...y Genomics-Based Medicine Project. The project is ...d academic centers working to improve treatment an...earch site in the Southeast. UAB is one of four co...
...r Engines, and Nominate Now at ..., one of the most trusted brands,for indigestion a...rch for,one lucky fan to serve as the Grand Marsha...cgi-bin/prnh/20080709/AQW525 ), "TUMS, and the al...
Other Medicine News:Health News:ELS Plus CPR Boosts Blood Flow After Cardiac Arrest 2Health News:Global Industry Analysts' Releases a Series of Medical Market Research Reports 2Health News:Global Industry Analysts' Releases a Series of Medical Market Research Reports 3Health News:Minnesota Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Blue Cross and Blue Shield of Illinois Gives $960,000 in Charitable Donations 2Health News:Blue Cross and Blue Shield of Illinois Gives $960,000 in Charitable Donations 3Health News:UAB joins elite brain cancer research group 2Health News:TUMS Announces Nationwide Search for Grand Marshal at TUMS QuikPak 500 2
Full Handle Laseredge Implant Blade Knife, 3.2 mm round tip
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up
Full Handle Laseredge Crescent Blade Knife, angled bevel down
Medicine Products: